Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 4/20 | 0.62 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.58 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.58 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CNR1 | P21554 | 2/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.51 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4912512 | 1.00 | PRKCA (0.62) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL10896003 | 1.00 | PRKCA (0.62) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL4912502 | 1.00 | PRKCA (0.62) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL6798442 | 0.93 | LPAR1 (0.55) | PRKCAALDH1A1LPAR1LPAR3 | |
| SCHEMBL6798446 | 0.93 | LPAR1 (0.55) | PRKCAALDH1A1LPAR1LPAR3 | |
| SCHEMBL7411764 | 0.91 | PRKCA (0.65) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL1008410 | 0.91 | PRKCA (0.65) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL5493689 | 0.91 | PRKCA (0.65) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL2732833 | 0.91 | PRKCA (0.65) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL27795601 | 0.91 | PRKCA (0.65) | PRKCAPRKCEPRKCQPRKCDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021377-A1 | USE OF A TRPC CHANNEL FOR THE TREATMENT OF A CARDIOVASCULAR DISEASE | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | claimed |
| US-20080221025-A1 | Use of Trpc Channel for the Treatment of a Cardiovascular Disease | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-09-11 | — | — | US | claimed |
| EP-1838334-A1 | USE OF A TRPC CHANNEL FOR THE TREATMENT OF A CARDIOVASCULAR DISEASE | Sanofi-Aventis (FR) | 2007-10-03 | — | — | EP | claimed |
| WO-2006074802-A1 | USE OF A TRPC CHANNEL FOR THE TREATMENT OF A CARDIOVASCULAR DISEASE | SANOFI-AVENTIS (FR) | 2006-07-20 | — | — | WO | claimed |
| EP-1066834-A2 | Pharmaceutical compositions comprising a phagocyte-modulating agent | Stief, Thomas, Dr. (DE) | 2001-01-10 | — | — | EP | claimed |
| US-20220308068-A1 | BIOMARKER IN OSTEOPOROSIS INTERVENTION THERAPY BY BONE PEPTIDE, SCREENING METHOD AND USE THEREOF | Institute of Food Science and Technology, Chinese Academy of Agricultural Sciences (CN) | 2022-09-29 | — | — | US | disclosed |
| US-10765670-B2 | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2020-09-08 | — | — | US | disclosed |
| EP-2773337-B1 | USE OF ANTI-CONNEXIN AGENTS FOR ENHANCING THE THERAPEUTIC EFFECT OF ACETYLCHOLINESTERASE INHIBITORS | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2018-09-19 | — | — | EP | disclosed |
| US-20180177773-A1 | USE OF ANTI-CONNEXIN AGENTS FOR ENHANCING THE THERAPEUTIC EFFECT OF ACETYLCHOLINESTERASE INHIBITORS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2018-06-28 | — | — | US | disclosed |
| US-20150011584-A1 | USE OF ANTI-CONNEXIN AGENTS FOR ENHANCING THE THERAPEUTIC EFFECT OF ACETYLCHOLINESTERASE INHIBITORS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-01-08 | — | — | US | disclosed |
| EP-2205247-B1 | USE OF NORGESTIMATE AS A SELECTIVE INHIBITOR OF TRPC3, TRPC6 AND TRPC7 ION CHANNELS | SANOFI SA (FR) | 2013-07-31 | — | — | EP | disclosed |
| US-8455469-B2 | Use of norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC7 ion channels | SANOFI (FR) | 2013-06-04 | — | — | US | disclosed |
| WO-2009052972-A2 | USE OF NORGESTIMATE AS A SELECTIVE INHIBITOR OF TRPC3, TRPC6 AND TRPC7 ION CHANNELS | SANOFI-AVENTIS (FR) | 2009-04-30 | — | — | WO | disclosed |
| EP-2052724-A1 | Use of norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC6 and TRPC7 ion channel | sanofi-aventis (FR) | 2009-04-29 | — | — | EP | disclosed |
| US-20080221025-A1 | Use of Trpc Channel for the Treatment of a Cardiovascular Disease | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
| EP-1838334-A1 | USE OF A TRPC CHANNEL FOR THE TREATMENT OF A CARDIOVASCULAR DISEASE | Sanofi-Aventis (FR) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006074802-A1 | USE OF A TRPC CHANNEL FOR THE TREATMENT OF A CARDIOVASCULAR DISEASE | SANOFI-AVENTIS (FR) | 2006-07-20 | — | — | WO | disclosed |
| EP-0726761-B1 | MICROPARTICULAR PHARMACEUTICAL COMPOSITIONS IN MICELLAR FORM | ISOMED INC (US) | 2001-01-10 | — | — | EP | disclosed |
| EP-1066834-A2 | Pharmaceutical compositions comprising a phagocyte-modulating agent | Stief, Thomas, Dr. (DE) | 2001-01-10 | — | — | EP | disclosed |
| US-5858398-A | MICROPARTICLES CONTAINING ACTIVE AGENT, MIXTURE OF PHOSPHOLIPIDS, MIXTURE OF NONIONIC SURFACTANTS, STEROL SUSPENDED IN FATTY ACID | ISOMED INC. (US) | 1999-01-12 | — | — | US | disclosed |